Literature DB >> 20467927

Blood glucose control and coronary heart disease.

Cristina Bianchi1, Giuseppe Penno, Roberto Miccoli, Stefano Del Prato.   

Abstract

Epidemiologic data support the hypothesis of a direct and independent relationship between hyperglycemia and cardiovascular disease. The lack of a clear-cut threshold value in diabetic patients, and the persistence of the relationship in nondiabetic population as well, suggest that glycemia is a continuous variable, similarly to other cardiovascular risk factors. Moreover, increased plasma glucose levels contribute to cardiovascular risk by activating multiple atherogenic mechanisms. In spite of evident plausibility for hyperglycemia as a cardiovascular risk factor per se, intervention data remain controversial. Results of recent large-scale intervention trials, such as ACCORD, ADVANCE, and VADT, seem to undermine the concept that tight glycemic control confers some protection against cardiovascular disease in patients with type 2 diabetes, while maintenance of near-normal glycemic control from earlier stage of the disease and during acute coronary events seems to be more beneficial. However, individualized therapies remain the cornerstone of strategies aimed to reduce cardiovascular risk associated to hyperglycemia.

Entities:  

Mesh:

Year:  2010        PMID: 20467927     DOI: 10.1007/s00059-010-3340-4

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  102 in total

1.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

Authors:  George G Sokos; Lazaros A Nikolaidis; Sunil Mankad; Dariush Elahi; Richard P Shannon
Journal:  J Card Fail       Date:  2006-12       Impact factor: 5.712

2.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

3.  Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.

Authors:  Elizabeth Selvin; Michael W Steffes; Hong Zhu; Kunihiro Matsushita; Lynne Wagenknecht; James Pankow; Josef Coresh; Frederick L Brancati
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

4.  Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting.

Authors:  Anthony P Furnary; Guangqiang Gao; Gary L Grunkemeier; YingXing Wu; Kathryn J Zerr; Stephen O Bookin; H Storm Floten; Albert Starr
Journal:  J Thorac Cardiovasc Surg       Date:  2003-05       Impact factor: 5.209

5.  Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events?

Authors:  Rebecca K Simmons; Stephen Sharp; S Matthijs Boekholdt; Lincoln A Sargeant; Kay-Tee Khaw; Nicholas J Wareham; Simon J Griffin
Journal:  Arch Intern Med       Date:  2008-06-09

6.  Prognostic value of admission blood glucose concentration and diabetes diagnosis on survival after acute myocardial infarction: results from 4702 index cases in routine practice.

Authors:  Ian B Squire; Christopher P Nelson; Leong L Ng; David R Jones; Kent L Woods; Paul C Lambert
Journal:  Clin Sci (Lond)       Date:  2010-04       Impact factor: 6.124

7.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

8.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

9.  Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.

Authors:  Rafael Díaz; Abhinav Goyal; Shamir R Mehta; Rizwan Afzal; Denis Xavier; Prem Pais; Susan Chrolavicius; Jun Zhu; Khawar Kazmi; Lisheng Liu; Andrzej Budaj; Mohammad Zubaid; Alvaro Avezum; Mikhail Ruda; Salim Yusuf
Journal:  JAMA       Date:  2007-11-28       Impact factor: 56.272

10.  Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects.

Authors:  Auni Juutilainen; Seppo Lehto; Tapani Rönnemaa; Kalevi Pyörälä; Markku Laakso
Journal:  Diabetes Care       Date:  2007-12-14       Impact factor: 19.112

View more
  4 in total

1.  Effects of eicosapentaenoic acid and vitamin C on glycemic indices, blood pressure, and serum lipids in type 2 diabetic Iranian males.

Authors:  Mohammad Mehdi Shakouri Mahmoudabadi; Mahmoud Djalali; Seyed Abolghassem Djazayery; Seyed Ali Keshavarz; Mohammad Reza Eshraghian; Ali Akbar Saboor Yaraghi; Gholamreza Askari; Reza Ghiasvand; Mahnaz Zarei
Journal:  J Res Med Sci       Date:  2011-03       Impact factor: 1.852

Review 2.  Tight glycemic control and cardiovascular effects in type 2 diabetic patients.

Authors:  Latha Subramanya Moodahadu; Ruchi Dhall; Abdul Hamid Zargar; Sudhakar Bangera; Lalitha Ramani; Ramesh Katipally
Journal:  Heart Views       Date:  2014 Oct-Dec

3.  Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study.

Authors:  Martino Deidda; Antonio Noto; Christian Cadeddu Dessalvi; Daniele Andreini; Felicita Andreotti; Eleuterio Ferrannini; Roberto Latini; Aldo P Maggioni; Marco Magnoni; Giuseppe Mercuro
Journal:  Metabolites       Date:  2022-01-27

4.  The effect of simvastatin on glucose homeostasis in streptozotocin induced type 2 diabetic rats.

Authors:  Lulu Wang; Guanglan Duan; Yong Lu; Shuguang Pang; Xianping Huang; Qiang Jiang; Ningning Dang
Journal:  J Diabetes Res       Date:  2013-02-25       Impact factor: 4.011

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.